Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India
Bigul

Q4FY23 Quarterly & FY23 Annual Result Announced for Eris Lifesciences Ltd.

 Pharmaceuticals firm Eris Lifesciences announced Q4FY23 & FY23 results: Organic standalone revenue growth - 11.5% (Q4), 9.5% (FY23) & 15.6% (FY23) Consolidated Revenue growth at Rs 4,028 million - 32% (Q4), 25% (FY23), and 31% (FY23) Top-20 Eris mother brands accounting for 70% of revenue grew organically by 17% in FY23 Eris MJ (Insulin Business) organically clocks Rs 17 crore revenue in first year of commercial operations Achieved organic growth of 22% in Oaknet base business after 3 flat years during FY20-FY22; full year FY23 Revenue Rs 250 crore (28% growth) with EBIDTA Rs 61 crore (margin 24.4%) Amortisation of Glenmark & DRL brands has been charged for 6 months of FY23 as per statutory requirements; however financial upside from the deals has been minimal during FY23 since the deals were consummated in Q4FY23 Result PDF
17-05-2023
Bigul

Eris Lifesciences Ltd - 540596 - Announcement under Regulation 30 (LODR)-Investor Presentation

 Dear Sir/Madam, Pursuant to the requirement of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached investor presentation made by the Company. Thanking you.
17-05-2023
Bigul

Eris Lifesciences Ltd - 540596 - OUTCOME OF THE BOARD MEETING

 In accordance with the provisions of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors of the Company at their meeting held on 17th May, 2023 has, inter alia, transacted the following business: The Board of Directors duly approved and took on record the Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2023. We hereby declare that M/s. Deloitte Haskins & Sells LLP, Chartered Accountants, Statutory Auditors of the Company has issued its Audit Report with unmodified opinion on the Standalone and Consolidated Financial Results of the Company for the year ended 31st March, 2023. The duly signed Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2023 along with the Auditor''s Report are enclosed. The meeting of Board of Directors commenced on 11:00 A.M. and concluded on 02:20 P.M.
17-05-2023
Bigul

Eris Lifesciences Ltd - 540596 - Board Meeting Outcome for OUTCOME OF THE BOARD MEETING

 In accordance with the provisions of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors of the Company at their meeting held on 17th May, 2023 has, inter alia, transacted the following business: The Board of Directors duly approved and took on record the Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2023. We hereby declare that M/s. Deloitte Haskins & Sells LLP, Chartered Accountants, Statutory Auditors of the Company has issued its Audit Report with unmodified opinion on the Standalone and Consolidated Financial Results of the Company for the year ended 31st March, 2023. The duly signed Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2023 along with the Auditor''s Report are enclosed. The meeting of Board of Directors commenced on 11:00 A.M. and concluded on 02:20 P.M.
17-05-2023
Bigul

Annual report for Eris Lifesciences Ltd. for FY-2023
17-05-2023
Bigul

Eris Lifesciences Ltd - 540596 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Dear Sir/Madam, This is further to our letter dated 10th May 2023 intimating about the date of the Board of Directors Meeting to, inter alia, consider and approve the standalone and consolidated audited financial results of the Company for the quarter and financial year ended 31 March, 2023. We wish to inform that pursuant to regulation 30 and other applicable regulations, if any, of the SEBI (LODR) Regulations, 2015, the Company will hold a conference call for analysts and investors on Wednesday, 17th May, 2023 at 05:00 p.m., IST. The details of the said call are attached herewith and also available on Company's website. Thanking you. For Eris Lifesciences Limited
12-05-2023
Bigul

Eris Lifesciences Ltd - 540596 - Board Meeting Intimation for Consideration And Approval Of The Standalone And Consolidated Audited Financial Results Of The Company For The Quarter And Year Ended 31St March, 2023.

 Eris Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 17/05/2023 ,inter alia, to consider and approve the standalone and consolidated audited financial results of the Company for the quarter and year ended 31st March, 2023.
10-05-2023
Bigul

Eris Lifesciences Ltd - 540596 - Announcement under Regulation 30 (LODR)-Credit Rating

 Dear Sir/Madam, In accordance with the applicable requirements and regulations of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and other applicable Regulations, if any, we hereby notify the assignment of rating to the Company by India Rating & Research which appears at the following link: Link: India Ratings Assigns Eris Lifesciences 'IND AA-'/Stable Thanking You,
05-05-2023
Bigul

Eris Lifesciences Ltd - 540596 - Compliance Certificate - Regulation 40(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

 Compliance Certificate - Regulation 40(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
28-04-2023
Bigul

Eris Lifesciences Ltd - 540596 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A

 Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyEris Lifesciences Ltd 2CIN NO.L24232GJ2007PLC049867 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 262.50 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Milind Talegaonkar Designation: Company Secretary and Compliance Officer EmailId: complianceofficer@erislifesciences.com Name of the Chief Financial Officer: Sachin Shah Designation: Chief Financial Officer EmailId: Sachin@erislifesciences.com Date: 26/04/2023 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
26-04-2023
Next Page
Close

Let's Open Free Demat Account